Pramlintide
Also known as: Symlin, AC137, synthetic amylin
Pramlintide (Symlin) is an FDA-approved prescription medication. This profile is for research and educational context only.
Overview
Synthetic amylin analogue (Symlin) approved as an adjunct to insulin for both type 1 and type 2 diabetes. Amylin is normally co-secreted with insulin from pancreatic beta cells, but is deficient in T1D (beta cell destruction) and reduced in T2D. Pramlintide replaces this missing signal to reduce post-meal glucose spikes and food intake.
Research Summary
Pramlintide reduces post-prandial glucose by three complementary mechanisms: slowing gastric emptying, suppressing post-meal glucagon secretion from alpha cells, and signaling meal-related satiety via brainstem amylin receptors. Phase 3 trials in both T1D and T2D demonstrated HbA1c reductions of 0.3–0.5% when added to insulin, with additional weight loss of 1–3kg — a welcome effect contrasting with insulin's typical weight gain.
Dosing Range
low
15mcg
moderate
60mcg
high
120mcg
Units: mcg · Frequency: Before major meals (3x daily)
Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.
Administration Routes
Reconstitution Notes
Supplied as solution in vials or SoloStar pen. Cannot be mixed with insulin — pH incompatibility causes precipitation. Use separate injection sites. Administer ≥2 inches from insulin injection site.Step-by-step reconstitution guide →
Supplies you'll need
Affiliate links — Research Stack may earn a small commission at no extra cost to you.
Reported Side Effects
- Nausea (most common, often transient in first 4 weeks)
- Hypoglycemia risk (when combined with insulin — insulin dose reduction required)
- Vomiting
- Decreased appetite
- Headache
- Injection fatigue (additional pre-meal injections)
Research Papers
2 peer-reviewed sourcesCommunity Experiences
Aggregated from public forums. Anecdotal — not clinical evidence.
T1D community experiences with Symlin for post-meal glucose control, managing nausea, and insulin dose adjustment.
View original threadT2D reports on adding pramlintide to insulin regimens for weight management and glucose control.
View original threadOverview
Pramlintide (Symlin) addresses a gap in insulin therapy that standard insulin replacement cannot fill. In healthy people, the pancreatic beta cells co-secrete two hormones simultaneously when stimulated by a meal: insulin and amylin. Insulin handles glucose disposal; amylin handles the peri-meal regulation of gastric emptying, glucagon, and satiety.
In type 1 diabetes, beta cell destruction eliminates both insulin and amylin secretion. Standard insulin therapy replaces insulin but leaves the amylin deficiency unaddressed — meaning post-meal glucose spikes remain problematic despite insulin coverage. Pramlintide closes this gap.
In type 2 diabetes, beta cell dysfunction reduces amylin secretion proportionally to insulin secretion loss, and patients on insulin who are amylin-deficient can similarly benefit.
Mechanism
Three Complementary Post-Meal Actions
1. Gastric Emptying Delay Pramlintide slows the rate at which food leaves the stomach and enters the small intestine. This:
- Blunts the post-meal glucose absorption curve
- Reduces peak post-meal glucose concentrations
- Allows co-administered insulin more time to act before glucose rises sharply
2. Glucagon Suppression Normally, meals trigger insulin while glucagon from alpha cells is suppressed. In T1D and advanced T2D, this glucagon suppression is impaired. Pramlintide restores appropriate post-meal glucagon suppression, reducing hepatic glucose output during the post-meal window.
3. Satiety Signaling Amylin receptors in the brainstem area postrema and hypothalamus receive post-meal satiety signals. Pramlintide activates these receptors, contributing to reduced caloric intake and the observed weight loss in clinical trials.
The Amylin-Insulin Interaction
A critical practical consideration: pramlintide and insulin cannot be mixed in the same syringe. They have different pH requirements for stability — mixing causes pramlintide to precipitate and lose activity. Separate injections at different sites are required.
Additionally, insulin doses typically require reduction (30–50%) when pramlintide is initiated to prevent hypoglycemia, as the additive glucose-lowering effects can be significant.
Comparison: Amylin Agonists in Development
| Compound | Status | Frequency | Notes | |----------|--------|-----------|-------| | Pramlintide | FDA-approved (2005) | TID (pre-meal) | T1D + T2D | | Cagrilintide | Phase 3 | Once weekly | Long-acting; CagriSema combo | | Native amylin | Research reference | N/A | Rapid aggregation; not usable |
Related Metabolic Peptides
AOD-9604
MetabolicAnti-Obesity Drug 9604 · hGH Fragment 176-191
AOD-9604 is a modified fragment of the C-terminus of human growth hormone (hGH), specifically amino acids 176–191. It wa…
MOTS-c
MetabolicMitochondrial Open Reading Frame of the 12S rRNA-c · MOTS-c peptide
MOTS-c is a mitochondria-derived peptide encoded in the 12S ribosomal RNA gene of mitochondrial DNA. It translocates to…
PT-141
MetabolicBremelanotide · Vyleesi
PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder (…